医学
胰腺癌
预期寿命
化疗
肿瘤科
癌症
药品
内科学
重症监护医学
药理学
人口
环境卫生
作者
Aurélien Lambert,Thierry Conroy,Michel Ducreux
标识
DOI:10.1053/j.seminoncol.2021.02.002
摘要
Pancreatic cancer is still one of the most lethal cancers with a reported 5-year relative survival rate of approximatively 9% and medical treatment remains a major challenge. Systemic treatment is recommended in every setting: resectable, borderline resectable, locally advanced and metastatic. Yet, few groundbreaking changes in practice have occurred in the last 30 years compared to other cancers and new treatments options are highly desirable. Most treatment approaches using chemotherapy have failed to improve patients' life expectancy and the few therapies finally found to have statistically significant benefit actually have modest clinical impact. It is becoming imperative to find new paths for improvement, such as encapsulated agents, new generation targeted therapies and treatments directed against the tumor microenvironment. We report here the new drugs of interest in pancreatic cancer and analyze the most recent failures.
科研通智能强力驱动
Strongly Powered by AbleSci AI